Published in J Infect Dis on May 24, 2007
Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med (2009) 3.38
Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog (2010) 1.96
Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis (2011) 1.68
Drug resistance and genetic mapping in Plasmodium falciparum. Curr Genet (2008) 1.36
Hitchhiking and selective sweeps of Plasmodium falciparum sulfadoxine and pyrimethamine resistance alleles in a population from central Africa. Antimicrob Agents Chemother (2008) 1.34
Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987--2006. J Infect Dis (2008) 1.32
Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology (2011) 1.28
Selective sweeps and genetic lineages of Plasmodium falciparum drug -resistant alleles in Ghana. J Infect Dis (2011) 1.26
Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay. Am J Trop Med Hyg (2008) 1.23
Adaptive evolution and fixation of drug-resistant Plasmodium falciparum genotypes in pregnancy-associated malaria: 9-year results from the QuEERPAM study. Infect Genet Evol (2011) 1.21
Evolutionary biology and the avoidance of antimicrobial resistance. Evol Appl (2009) 1.16
Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia. J Infect Dis (2010) 1.12
Differences in selective pressure on dhps and dhfr drug resistant mutations in western Kenya. Malar J (2012) 1.09
Indigenous evolution of Plasmodium falciparum pyrimethamine resistance multiple times in Africa. J Antimicrob Chemother (2008) 1.03
High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar J (2013) 1.01
Multiple origins of Plasmodium falciparum dihydropteroate synthetase mutant alleles associated with sulfadoxine resistance in India. Antimicrob Agents Chemother (2011) 0.99
Longitudinal survey of Plasmodium falciparum infection in Vietnam: characteristics of antimalarial resistance and their associated factors. J Clin Microbiol (2009) 0.99
Independent origin of plasmodium falciparum antifolate super-resistance, Uganda, Tanzania, and Ethiopia. Emerg Infect Dis (2014) 0.95
Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations. Pediatr Res (2009) 0.94
Characteristics of genetic hitchhiking around dihydrofolate reductase gene associated with pyrimethamine resistance in Plasmodium falciparum isolates from India. Antimicrob Agents Chemother (2009) 0.93
Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin. Antimicrob Agents Chemother (2013) 0.91
Antifolate resistance in Africa and the 164-dollar question. Trans R Soc Trop Med Hyg (2008) 0.90
Reduced efficacy of intermittent preventive treatment of malaria in malnourished children. Antimicrob Agents Chemother (2009) 0.89
In vitro susceptibility to pyrimethamine of DHFR I164L single mutant Plasmodium falciparum. Malar J (2011) 0.86
The evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection under SP alone vs SP+artesunate combination. Malar J (2011) 0.86
Tracing the origins and signatures of selection of antifolate resistance in island populations of Plasmodium falciparum. BMC Infect Dis (2010) 0.86
Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. Int J Parasitol Drugs Drug Resist (2012) 0.83
Origins of the recent emergence of Plasmodium falciparum pyrimethamine resistance alleles in Madagascar. Antimicrob Agents Chemother (2010) 0.81
Genetic diversity and signatures of selection of drug resistance in Plasmodium populations from both human and mosquito hosts in continental Equatorial Guinea. Malar J (2013) 0.81
Transmission and cross-mating of high-level resistance Plasmodium falciparum dihydrofolate reductase haplotypes in The Gambia. Am J Trop Med Hyg (2010) 0.80
Identification of pyrimethamine- and chloroquine-resistant Plasmodium falciparum in Africa between 1984 and 1998: genotyping of archive blood samples. Malar J (2011) 0.80
Distinctive origin and spread route of pyrimethamine-resistant Plasmodium falciparum in southern China. Antimicrob Agents Chemother (2013) 0.79
Molecular monitoring of resistant dhfr and dhps allelic haplotypes in Morogoro and Mvomero districts in south eastern Tanzania. Afr Health Sci (2011) 0.78
Low-grade sulfadoxine-pyrimethamine resistance in Plasmodium falciparum parasites from Lubango, Angola. Malar J (2016) 0.75
Drug-resistant malaria in Sudan: A review of evidence and scenarios for the future. Sudan J Paediatr (2012) 0.75
The pathogenic basis of malaria. Nature (2002) 10.44
Phylogenomics revives traditional views on deep animal relationships. Curr Biol (2009) 5.89
A research agenda to underpin malaria eradication. PLoS Med (2011) 5.34
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis (2003) 5.21
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med (2007) 2.94
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis (2008) 2.77
Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. Trop Med Int Health (2005) 2.57
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol (2011) 2.54
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J (2008) 2.49
Risk factors for malaria infection and anemia for pregnant women in the Sahel area of Bandiagara, Mali. Acta Trop (2003) 2.47
Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol (2009) 2.43
False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the hrp2 gene. Am J Trop Med Hyg (2012) 2.43
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med (2005) 2.33
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.29
Malaria transmission dynamics at a site in northern Ghana proposed for testing malaria vaccines. Trop Med Int Health (2004) 2.28
Ethical data release in genome-wide association studies in developing countries. PLoS Med (2009) 2.23
Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Mol Biochem Parasitol (2006) 2.22
A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med (2009) 2.21
Space-time clustering of childhood malaria at the household level: a dynamic cohort in a Mali village. BMC Public Health (2006) 2.20
Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A (2008) 2.19
Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature (2005) 2.17
Valid consent for genomic epidemiology in developing countries. PLoS Med (2007) 2.14
A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine (2009) 2.12
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog (2010) 2.03
Community permission for medical research in developing countries. Clin Infect Dis (2005) 2.01
Malaria-induced acquisition of antibodies to Plasmodium falciparum variant surface antigens. Infect Immun (2002) 2.00
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg (2008) 1.95
Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med (2009) 1.95
Seasonal malaria attack rates in infants and young children in northern Ghana. Am J Trop Med Hyg (2002) 1.91
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One (2008) 1.90
Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg (2002) 1.88
No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg (2012) 1.87
Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis (2005) 1.86
Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. Am J Trop Med Hyg (2005) 1.86
Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med (2007) 1.78
Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in mali: a randomized controlled trial. Clin Infect Dis (2011) 1.74
A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg (2008) 1.72
An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis (2013) 1.72
Hemoglobin S and C heterozygosity enhances neither the magnitude nor breadth of antibody responses to a diverse array of Plasmodium falciparum antigens. J Infect Dis (2011) 1.71
Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine (2004) 1.70
Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am J Trop Med Hyg (2007) 1.69
Malaria and the red cell. Hematology Am Soc Hematol Educ Program (2002) 1.64
PfCRT and its role in antimalarial drug resistance. Trends Parasitol (2012) 1.63
Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. Am J Trop Med Hyg (2003) 1.58
A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog (2007) 1.56
The etiology of severe anemia in a village and a periurban area in Mali. Blood (2004) 1.55
Seeking consent to genetic and genomic research in a rural Ghanaian setting: a qualitative study of the MalariaGEN experience. BMC Med Ethics (2012) 1.55
Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity. Am J Trop Med Hyg (2007) 1.55
Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS One (2008) 1.54
Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda. Am J Trop Med Hyg (2005) 1.53
Heparan sulfate on endothelial cells mediates the binding of Plasmodium falciparum-infected erythrocytes via the DBL1alpha domain of PfEMP1. Blood (2002) 1.51
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
PfEMP1-DBL1alpha amino acid motifs in severe disease states of Plasmodium falciparum malaria. Proc Natl Acad Sci U S A (2007) 1.47
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials (2006) 1.47
Epilepsy as a consequence of cerebral malaria in area in which malaria is endemic in Mali, West Africa. Epilepsia (2006) 1.45
A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg (2006) 1.41
A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa. Malar J (2006) 1.41
In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun (2009) 1.39
An effective method to purify Plasmodium falciparum DNA directly from clinical blood samples for whole genome high-throughput sequencing. PLoS One (2011) 1.39
Genome wide gene amplifications and deletions in Plasmodium falciparum. Mol Biochem Parasitol (2007) 1.37
Different antibody- and cytokine-mediated responses to Plasmodium falciparum parasite in two sympatric ethnic tribes living in Mali. Microbes Infect (2004) 1.36
Characterization of within-host Plasmodium falciparum diversity using next-generation sequence data. PLoS One (2012) 1.36
Induction of strain-transcending antibodies against Group A PfEMP1 surface antigens from virulent malaria parasites. PLoS Pathog (2012) 1.35
Combined deletions of pfhrp2 and pfhrp3 genes result in Plasmodium falciparum malaria false-negative rapid diagnostic test. J Clin Microbiol (2011) 1.34
Origin and evolution of the Notch signalling pathway: an overview from eukaryotic genomes. BMC Evol Biol (2009) 1.34
Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. Am J Trop Med Hyg (2006) 1.33
Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana. PLoS One (2011) 1.31
Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis (2013) 1.30
Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis (2012) 1.30
Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J (2010) 1.27
First detection of Leishmania major DNA in Sergentomyia (Spelaeomyia) darlingi from cutaneous leishmaniasis foci in Mali. PLoS One (2012) 1.26
Malaria incidence in relation to rice cultivation in the irrigated Sahel of Mali. Acta Trop (2004) 1.25
Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. J Infect Dis (2004) 1.25
Prevalence of latent and reactivated Toxoplasma gondii parasites in HIV-patients from Uganda. Acta Trop (2006) 1.24
Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS One (2010) 1.22
Common trafficking pathway for variant antigens destined for the surface of the Plasmodium falciparum-infected erythrocyte. Mol Biochem Parasitol (2004) 1.21
Sp1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes. J Biol Chem (2003) 1.21
A positive correlation between atypical memory B cells and Plasmodium falciparum transmission intensity in cross-sectional studies in Peru and Mali. PLoS One (2011) 1.21
Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis (2006) 1.19
Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malar J (2010) 1.19
Nonimmune immunoglobulin binding and multiple adhesion characterize Plasmodium falciparum-infected erythrocytes of placental origin. Proc Natl Acad Sci U S A (2006) 1.18
Filaria-induced monocyte dysfunction and its reversal following treatment. Infect Immun (2006) 1.16
Modelling malaria incidence with environmental dependency in a locality of Sudanese savannah area, Mali. Malar J (2009) 1.16
Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. Trop Med Int Health (2009) 1.14